Pet Immune Drugs

Beyond developing novel and potentially improved treatment options for human patients, we expanded our pipeline portfolio to pet immune drugs by deploying our deep understanding of immunology and our accumulated experience in the research and development of small molecule drug candidates.

GGW101  Lirucitinib : A small molecule JAK inhibitor for canine pruritus

Canine pruritus is an unpleasant sensation within the skin that provokes the desire to scratch and can be acute or chronic. The major causes of canine pruritus include parasites, infections, and allergies.

We received an approval in March 2022 from Beijing Municipal Bureau of Agriculture and Rural Affairs to commence the Phase I clinical trial of GGW101 in China.  And Lirucitinib has received the approval from the Ministry of Agriculture and Rural Affairs of China for Class I New Veterinary Drug Certificate for the treatment of canine pruritus in October 2024. 

GGW102: A small molecule immune checkpoint inhibitor for feline infectious peritonitis

Feline infectious peritonitis is an immune-mediated disease in cats caused by certain strains of feline coronavirus (FCoV), and is fatal in most cases.

According to Frost & Sullivan, as of January 2023, no effective treatment for feline infectious peritonitis was available worldwide. GGW102 is a small molecule immune checkpoint inhibitor candidate for feline infectious peritonitis and is a Class 1.1 novel veterinary chemical drug. We received an approval in January 2022 from Beijing Municipal Bureau of Agriculture and Rural Affairs to commence the Phase I clinical trial of GGW102 in China, the results of which demonstrated that GGW102 is well tolerated in domestic cats. We had completed Phase II clinical trial and the Phase III clinical trial of GGW102 is undergoing to further investigate its safety and efficacy.